Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 405552100 since 12/18/2024, newest first.
| Filer | % of Class | Filed |
|---|---|---|
| Pfizer Inc. 13D/A Amendment 15 | 0% |
3/24/2025
Event 3/21/2025
|
| Pfizer Inc. 13D/A Amendment 14 | 7.3% |
3/20/2025
Event 3/18/2025
|
| Pfizer Inc. 13D/A Amendment 13 | 7.3% |
2/27/2025
Event 2/25/2025
|
| Pfizer Inc. 13D/A Amendment 12 | 7.3% |
1/21/2025
Event 1/17/2025
|
| Pfizer Inc. 13D/A Amendment 11 | 15.0% |
1/16/2025
Event 1/14/2025
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 216 | 36.6 M | $329 M |
| 2026 Q2 | 664 | 596 M | $5.56 B |
| 2026 Q1 | 642 | 568 M | $5.69 B |
| 2025 Q4 | 622 | 566 M | $5.72 B |
| 2025 Q3 | 617 | 563 M | $5.05 B |
| 2025 Q2 | 645 | 581 M | $6.02 B |
| 2025 Q1 | 616 | 570 M | $5.87 B |
| 2024 Q4 | 625 | 734 M | $7.01 B |
| 2024 Q3 | 604 | 521 M | $5.51 B |
| 2024 Q2 | 599 | 531 M | $4.40 B |
| 2024 Q1 | 618 | 524 M | $4.45 B |
| 2023 Q4 | 610 | 406 M | $3.34 B |
| 2023 Q3 | 586 | 391 M | $3.18 B |
| 2023 Q2 | 598 | 379 M | $3.17 B |
| 2023 Q1 | 594 | 372 M | $3.03 B |
| 2022 Q4 | 607 | 345 M | $2.76 B |
| 2022 Q3 | 565 | 309 M | $1.88 B |